NeoImmuneTech Inc (KOSDAQ: 950220), a US-based clinical-stage T cell-focused biopharmaceutical company, announced on Tuesday that it has named Luke Oh, PhD as its new president and chief executive officer (CEO).
Dr Oh is to succeed Dr Se Hwan Yang, PhD. In the new role, Dr. Oh will head the company from its Rockville headquarters and oversee all of the company's Korea operations.
With more than six years of regulatory experience at the US FDA, Dr Oh has also served as vice-president in charge of Regulatory Development at Samsung Bioepis, senior staff fellow at the US FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and in various roles in research and development for leading organisations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences and Vertex Pharmaceuticals.
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
PRISM BioLab agrees drug discovery collaboration with Elix
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Genflow Biosciences enters into AI-driven research agreement with Heureka Labs
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Kyowa Kirin completes construction of new Drug Substance manufacturing facility
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
OncoZenge AB signs licensing deal with Avernus Pharma for BupiZenge in GCC region